Safety of Efalizumab in Patients with Moderate to Severe Chronic Plaque Psoriasis: Review of Clinical Data. Part II

By Papp Kim   Camisa Charles   Stone Stephen   Caro Ivor   Wang Xiaolin   Compton Peter   Walicke Patricia   Gottlieb Alice  

Journal of Cutaneous Medicine and Surgery, Vol. 9, Iss. 6, 2005-12 ,pp. : 313-323

Springer Publishing Company

Access to resources Recommend Favorite

The incidence of arthropathy adverse events in efalizumab-treated patients is low and similar to placebo and does not increase with long-term treatment: pooled analysis of data from Phase III clinical trials of efalizumab

By Pincelli Carlo  

Archives of Dermatological Research, Vol. 298, Iss. 7, 2006-12 ,pp. : 329-338

Springer Publishing Company

Access to resources Recommend Favorite

Impact of adalimumab treatment on patient-reported outcomes: Results from a Phase III clinical trial in patients with moderate to severe plaque psoriasis

By Revicki Dennis   Willian Mary Kaye   Menter Alan   Gordon Kenneth   Kimball Alexa   Leonardi Craig   Langley Richard   Kimel Miriam   Okun Martin  

Journal of Dermatological Treatment, Vol. 18, Iss. 6, 2007-01 ,pp. : 341-350

Informa Healthcare

Access to resources Recommend Favorite

A randomized, placebo-controlled trial of oral itraconazole in scalp psoriasis

By Jury CS   McHugh L   Shankland GS   Burden AD  

Journal of Dermatological Treatment, Vol. 11, Iss. 2, 2000-06 ,pp. : 85-89

Informa Healthcare

Access to resources Recommend Favorite

Topical TrkA Kinase Inhibitor CT327 is an Effective, Novel Therapy for the Treatment of Pruritus due to Psoriasis: Results from Experimental Studies, and Efficacy and Safety of CT327 in a Phase 2b Clinical Trial in Patients with Psoriasis

By Roblin David   Yosipovitch Gil   Boyce Brent   Robinson John   Sandy James   Mainero Valentina   Wickramasinghe Ro   Anand Uma   Anand Praveen  

Acta Dermato-Venereologica, Vol. 95, Iss. 5, 2015-05 ,pp. : 542-548

Medical Journals Limited

Access to resources Recommend Favorite